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Abstract
Background-: Hospital acquired infections are a major cause of morbidity and mortality and markedly increased
health care costs. Critically ill patients who require management in an Intensive Care Unit are particularly
susceptible to these infections which are associated with a very high mortality. Selective decontamination of the
digestive tract (SDD) may reduce these infections and improve mortality but it has not been widely adopted into
practice. We aim to 1. Clarify reasons why clinicians have avoided implementing SDD into clinical practice despite
the current best-evidence 2. Describe barriers to SDD implementation and 3. Identify what further evidence is
required before full scale clinical implementation would be considered appropriate and feasible.
Methods-: We have developed an international ‘multi-lens’ approach to investigate SDD from several perspectives.
In case studies we will identify accounts of implementation of SDD in practice, in terms of the behaviours
performed by the full range of individual clinicians, accounts of how SDD was first introduced into the Unit and
specific content that may be used to populate the content of behaviour change techniques to be used in an
implementation intervention and procedures to consider in order to deliver an implementation trial. In a 4 round
Delphi study we will identify the range of stakeholders’ beliefs, views and perceived barriers relating to the use of
SDD. We will generate hypotheses about key beliefs about SDD and will inform the feasibility of any future
randomised controlled trial. In large-scale nationwide postal questionnaire surveys of the state of current practice
we will identify the factors predicting acceptability of an effectiveness or implementation trial using, and informed
by, the theoretical domains structure. In semi-structured interviews with active international clinical trialists we will
assess the feasibility of a randomised controlled trial and identify challenges and barriers to undertaking research in
the field of SDD research.
Discussion: We believe these methods will allow us to determine whether clinical implementation trials or further
large effectiveness trials are required before full scale implementation into clinical practice.
Background
Each year in the UK 140,000 patients are admitted to an
intensive care unit (ICU) and of these almost 60,000 will
die within a year of admission. Hospital acquired infec-
tions (HAI) are a major clinical problem for modern
health services as they are associated with morbidity and
mortality as well as high additional health care costs. Cri-
tically ill patients are extremely susceptible to HAI and
these are associated with a high additional mortality,
prolonged hospital stays and a large health care resource
utilisation. Between 20 and 50% of ICU patients suffer
from such infections and major efforts are being underta-
ken to improve these outcomes [1,2].
An intervention that has gained much interest in redu-
cing HAI is selective decontamination of the digestive
tract (SDD). SDD involves the application of topical non-
absorbable antibiotics to the oropharynx and stomach
and a short course of intravenous antibiotics [3-14]. The
evidence base relating to SDD is reasonably strong with
12 meta-analyses of 28 randomised controlled studies in
the literature [3-14]. Ten of these studies demonstrate a
benefit in terms of reducing pneumonia rates and six
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studies show a specific mortality benefit in all ICU
patients or in major subgroups [3]. A very recent large
cluster randomised study from the Netherlands demon-
strated a 3.5% reduction in adjusted mortality associated
with SDD [14]. Problems with these meta-analyses
include clinical heterogeneity, lack of blinding and lack of
data on compliance with intervention. The Cochrane
review of SDD demonstrated an association with reduc-
tion in pneumonia, OR 0.32 (0.26-0.38) and death OR
0.75 (0.65-0.87) [3]. None of the published meta-analyses
included the recent cluster randomised study [14]. This
mortality benefit was present in the more recent rando-
mised studies and is of the magnitude of 3-6% absolute
risk reduction (ARR) with a number needed to treat
(NNT) of approximately 17 to save one life [3,14]. If this
mortality benefit could be realised in UK practice then it
could save as many as 2-3000 lives per annum. However,
these findings require to be confirmed in other health
care environments.
Despite this evidence base, ICU practitioners have not
widely adopted this intervention with only 10-15 ICUs
(out of 240) reporting that they undertake SDD in the
UK [14,15]. Existing surveys of practice have been
unable to fully elucidate the reasons for this lack of
adoption and implementation [14,15]. Reasons may
include fears over encouraging antibiotic resistance, a
lack of biological plausibility for the findings and a lack
of external validity of the evidence base since most of
the existing studies come from countries where infec-
tions due to multi-resistant organisms are uncommon
[14]. Finally, it is possible that this intervention is so
counterintuitive that clinicians will not change their
practice regardless of the evidence base or that one clin-
ician group could impede another group, who are in
favour of the intervention, from implementing it.
It seems that until there is high quality evidence
demonstrating clinical effectiveness, cost-effectiveness
and the ecological impact of SDD in a range of health
care systems, this intervention is unlikely to be imple-
mented and thus patients will be denied a potentially
life saving therapy. However, despite the clear impor-
tance of HAI in critically ill patients, and despite a
multi-national appreciation and prioritisation of the
importance and urgency of this research topic, it
remains unclear why this intervention has not been
implemented. Little is known about clinicians’ beliefs
about the existing evidence base, the perceived benefits
and risks of SDD in clinical practice, the factors that
influence current practice and likely barriers to imple-
mentation. Further, it is also unclear whether there is a
requirement for further high level evidence of effective-
ness before implementation would become acceptable
and what sort of study would be feasible and acceptable
to clinicians and trialists. This multi-method study will
address these issues in three regions (the UK, Canada
and Australia/New Zealand).
Aims
The overall aim of this study is to identify the perceived
risks, benefits and barriers to the use of SDD in critical
care units. To achieve this aim, the following objectives
are proposed (with formal research questions (RQs)
listed):
1. To identify and precisely describe the clinical inter-
vention in units and hospitals that deliver SDD:
• RQ1: What are the components of the intervention
of SDD?
• RQ2: How has SDD been implemented and deliv-
ered into practice?
2. To identify the range of beliefs, interpretation and
views about the current evidence base relating to the
use of SDD in key stakeholder groups:
• RQ3: What are the views of key stakeholders about
the likely positive and negative consequences of
implementing SDD in ICUs?
• RQ4: What are the views of key stakeholders about
the likely barriers to implementing SDD in ICUs?
• RQ5: What are the views of key stakeholders of
the internal/external validity and adequacy of the
existing evidence base for SDD?
3. To identify current practice and assess the accept-
ability of further randomised controlled trials in the
field of SDD in a wide group of intensive care clinicians
and infectious disease clinicians/medical microbiologists:
• RQ6: What are the current practices and inten-
tions of intensivists and infectious disease clinicians/
medical microbiologists about SDD?
• RQ7: If there are uncertainties in the evidence
base, do these clinicians believe they could be
addressed in a clinical trial and what research ques-
tions, trial design(s) and interventions would be opti-
mal and what predicts these beliefs?
4. To assess the feasibility of a proposed effectiveness
randomised controlled trial comparing SDD against a
control group in ICUs among international intensive
care clinical trialists:
• RQ8: What are the likely challenges in undertaking
a large multi-national randomised controlled study
of SDD in ICU?
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Methods
The study will use a ‘multi-lens’ approach to investigate
SDD from several perspectives and in three national
regions (the UK, Canada and Australia/New Zealand) to
allow greater understanding and international compari-
sons of the issues that relate to the implementation of
this therapy. The investigation will involve four inter-
related stages (Figure 1 shows a schema of this study).
Stage 1
Case studies will be conducted in units in which SDD has
been implemented (targeting RQs 1 and 2)
This stage will be conducted only in the UK region as
there are no adult critical care units in the other regions
who use SDD. The case studies will focus on a beha-
vioural analysis of the processes of implementation,
based on a modification of Michie and Johnston’s [16]
advice for specifying clinical behaviour (who, what, to
whom, when, how). It will identify the “A,B,C” (antece-
dents, behaviour, consequences)[17] of each action that
is taken in the sequence of behaviours between identify-
ing a patient who may be eligible for SDD, prescribing,
supplying, storing, communicating, administering (to the
patient) and so on, and the factors associated with the
‘flow’ between these actions. This will involve
observational visits, interviews with a range of clinical
staff (e.g. consultants, registrars, pharmacists, nurses etc)
and documentary analysis, which will be used to identify
the actions required from all staff to (a) introduce SDD
to the ICU and (b) maintain, regulate and optimise the
delivery of SDD over time. These case studies will
inform the practical issues around implementation of
SDD in ICUs either in the context of a trial intervention
or to inform implementation strategies. Two SDD units
will be purposively sampled from an existing database
from a national survey of SDD in the UK [15]. One
Unit that has recently implemented SDD and one that
has used SDD over a longer period will be identified.
When identified, SDD Units will be contacted and asked
to take part in the study. From multiple visits to each
site, structured observations of the administration of
SDD in the ICU will be followed by semi-structured
interviews with nursing staff, clinical leads and other
decision makers to elicit accounts of the processes of
change, including decision making, documentation and
resource issues. Retrospective accounts will be elicited,
describing how the Unit decided to introduce SDD, fac-
tors that triggered change, barriers experienced (i.e.,
interruptions to the ‘flow’ of actions), and the strategies
used to overcome them. The perceived consequences of
Figure 1 Design of study showing links to research questions.
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the SDD policy for the unit (and the hospital more gen-
erally) will be documented.
The case studies will identify accounts of implementa-
tion of SDD in practice, in terms of the behaviours per-
formed by the full range of individual clinicians;
accounts of how SDD was first introduced into the
Unit; specific content that may be used to populate the
content of behaviour change techniques to be used in
an implementation intervention and procedures to con-
sider in order to deliver an implementation trial.
Stage 2
A Delphi study to identify the range of stakeholders’ beliefs,
views and perceived barriers relating to the use of SDD
(targeting RQs 3, 4,5 and 7)
This stage will be conducted in all three regions. This
phase of the investigation will generate hypotheses
about key beliefs about SDD and will inform the feasi-
bility of any future randomised controlled trial. Using a
Delphi technique comprising an initial exploratory
‘round’ so that the full range of views may be raised and
then considered by all participants in later rounds, fol-
lowed by three iterations (i.e. four rounds in all), we will
sequentially build a picture of respondents’ beliefs and
views on SDD. We will further assess the likely factors
influencing the acceptability of any future randomised
controlled trial comparing SDD against a control group
(not including SDD) in ICUs and/or a proposed rando-
mised controlled trial comparing implementation strate-
gies for SDD against a control group in ICUs. Rounds 1
to 3 will be conducted independently within each
region, whilst round 4 will be multi-region.
There is a broad range of estimates of suitable sizes for a
Delphi panel, but smaller sizes (such as 10 per stakeholder
group) have been deemed appropriate where panel mem-
bers have similar training [18]. Four key stakeholder clini-
cian groups (ICU physicians, ICU pharmacists, infectious
disease clinicians/medical microbiologists, ICU clinical
managers) will be sampled using existing databases from
within each region. We will aim for 10 from each stake-
holder group. The total sample size will thus be approxi-
mately 40 in each of the three regions. Purposive diversity
sampling will be used in all groups to identify as wide a
range of initial views as possible, based on a range of vari-
ables: Academic-affiliated or not; years of experience (time
since commencing as consultant/other professional grade);
size of ICU (i.e. number of ICU beds); and current practice
(routinely perform SDD or not). During the interview
phase, diversity on these factors will be tracked using a
diversity sampling table and additional participants will be
invited to participate, if required, to maximise variation.
Transcribed interviews will be content analysed based on
the theoretical domains framework using methods
previously employed by the research team in the context
of critical care [19].
The Delphi study report will present (i) the perceived
importance of each specific belief about the use of SDD
in ICUs; (ii) the acceptability and feasibility of conduct-
ing an effectiveness trial; and (iii) the acceptability and
feasibility of conducting an implementation trial. In
round 4, the data from each regional setting will be pre-
sented to all international participants by email. The
international comparisons in this round are important,
to increase the generalisability of the results and of any
future study result, since lack of generalisability may
have been a major factor limiting the uptake and imple-
mentation of SDD in the past. This round will require
that the investigations conducted in each country use a
broadly parallel time frame, so that the feedback is pre-
sented to all participants with similar time intervals. The
full Delphi results will allow us to consider how best to
elaborate the key findings from the nationwide survey of
the state of current practice, described below.
Stage 3
Nationwide surveys of the state of current practice to
identify the factors predicting acceptability of an
effectiveness or implementation trial (targeting RQs 6 and 7)
This stage will be conducted in all three regions using
large-scale postal questionnaire surveys using existing
databases of intensivists and infectious disease clini-
cians/medical microbiologists in each region. This ques-
tionnaire design will be informed by the theoretical
domains structure [17] but only the domains identified
in the Delphi study as relevant to implementation of
SDD will be included. Questionnaire items will be devel-
oped using standard theory-based methods with a
7-point response format [20]. The exact content of the
questionnaire will be informed by the specific beliefs
and views identified as important in the Delphi, thereby
ensuring maximum relevance. The draft questionnaire
(and cover letter) will be pilot tested using one-to-one
interviews with 4 clinical collaborators to assess word-
ing, acceptability and length. An appropriate course of
action will then be agreed (i.e. accept, change, eliminate
etc). Reminder letters (up to a maximum of two) will be
posted to non-responders at two-week intervals after the
first posting. Analysis will include simple descriptive and
statistical prediction techniques [21-24]. These surveys
will attempt to establish the current state of practice in
ICUs with regard to SDD, the nature of evidence still
required and perceived barriers to implementation of
SDD. In addition, they will identify the willingness of
intensive care clinicians to participate in any future
effectiveness trial of SDD in intensive care practice and/
or an implementation trial of strategies to increase
Cuthbertson et al. Trials 2010, 11:117
http://www.trialsjournal.com/content/11/1/117
Page 4 of 7
uptake. The strongly predicting constructs and variables
will be targeted if this programme progresses to an
implementation trial, using systematic methods for
intervention development [22].
Stage 4
Semi-structured interviews with active clinical trialists in
intensive care to assess the feasibility of a randomised
controlled trial (targeting RQ 8)
Participants from all three regions as well as European
investigators will take part in this stage. We will inter-
view expert national and international clinical trialists in
the intensive care field including trialists with experience
in SDD to identify challenges and barriers to undertak-
ing research in the field of SDD research. We will seek
to recruit 10 participants from across the UK, Europe,
Canada and Australia. Semi-structured one-to-one inter-
views using a topic guide developed from the previous
phases as well as from expert experience will be used to
study this area. Questions will address potential trial
design issues (e.g. need for cluster randomisation), speci-
fication of the SDD intervention and of control group
care; outcome measurement; recruitment; ethical con-
siderations and other issues raised in the observational
and Delphi studies. Data will be transcribed and ana-
lysed using content analysis [25]. A full description of
the design and measurement issues to consider when
planning a possible effectiveness trial will be produced.
Outcome of project
This research will lead to an evidence-based decision
about whether to proceed to a clinical trial to evaluate
an SDD intervention or an implementation trial (i.e.,
development and evaluation of an intervention to
increase uptake of SDD in ICUs). The applicant team/
project steering group will make an assessment of
whether a trial is necessary, justifiable, acceptable and
feasible based on possible patterns of results from the
national surveys, for example:
1. If intention to implement SDD is low or variable,
and predicted by attitude scores and/or scores for speci-
fic beliefs about the consequences (benefits and harms)
of implementing SDD, it will be judged appropriate to
proceed to trial.
2. If intention to implement SDD is low or variable
and predicted by scores relating to social influence (e.g.
pressure from colleagues in other disciplines), this
would suggest that an implementation intervention
could be effective if delivered by an identified opinion
leader, clinical lead or local ‘champion’ through team
meetings. We would proceed to an implementation trial
to evaluate such an intervention.
3. If intention to implement SDD is low or variable
and predicted by beliefs relating to lack of capacity to
implement SDD (e.g. resource issues), this would sug-
gest that an implementation intervention could be effec-
tive if it focuses on barrier identification and generation
of strategies to overcome barriers, known as ‘coping
planning’ [26], we would proceed to an implementation
trial to evaluate such an intervention.
4. If intention to implement SDD is low or variable
and predicted (in the multi-level model) at the Unit
level, rather than by individual clinicians’ views of the
evidence, we would design an intervention directed at
ICUs rather than individual clinicians. This would be
informed by the behavioural analysis of SDD implemen-
tation in ICUs where it is currently practised. We would
proceed to an implementation trial to evaluate such an
intervention.
5. By contrast, if intention to implement SDD is high
(i.e., if there are ceiling effects and restricted variance),
then the current low level of implementation will be
attributable to an ‘intention-behaviour gap’, suggesting
that external barriers prevent clinicians from translating
their intentions into action. This pattern of results
would suggest that an implementation trial to test stra-
tegies for facilitating uptake would be appropriate.
Findings about acceptability and feasibility of a clinical
trial would also inform the decision about how best to
proceed. Specifically:
1. If willingness (intention) to participate in a trial is
low we will not proceed to a clinical trial.
2. If willingness (intention) to participate in a trial is
high this will indicate that the trial is sufficiently accep-
table to proceed. We will also take into account scores
for perceived ease or difficulty of participating.
We will also use the consensus data from the Delphi
study and the investigation of two ICUs where SDD has
been implemented, to decide: (i) behavioural (practical,
organisational and management) issues that would need
to be addressed in order to mount a trial; (ii) ethical
issues relating to informed acceptance of trial entry
among eligible patients; (iii) trial design issues including
measurement of outcome and process variables. If any
one stakeholder group seems to be uniformly of the opi-
nion that there are no design features that would make
a trial acceptable, and/or if a third (or more) of the
members of two (or more) groups deem any such trial
unacceptable, the clinical trial should not be pursued
further. Depending on the views expressed about the
existing evidence base (i.e. if treatment is viewed as
potentially beneficial) we will consider the place of an
implementation trial to change clinical practice. If
appropriate, the change techniques that would form the
components of such a trial will be selected using meth-
ods previously reported by members of the research
team [27,28]. The final decision on trial continuation
will be made by the study steering committee.
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Discussion
The issue of hospital acquired infections in critically ill
patients is a significant issue causing excess morbidity
and mortality as well as an excess health care delivery
costs. The intervention SDD has the promise to improve
these outcomes and is not widely used. This rigorous
multi-national study intends to identify the perceived
risks, benefits and barriers to the use of SDD in critical
care units. This research could lead to a variety of
further interventions including a multi-centre effective-
ness RCT or implementation study.
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